A recombinant truncated surface immunogenic protein (tSip) plus adjuvant FIA confers active protection against Group B streptococcus infection in tilapia

He, Yangyang; Wang, Kaiyu; Xiao, Dingquan; Chen, Defang; Huang, Lifei; Liu, Tianqiang; Wang, Junjun; Geng, Yi; Wang, Erlong; Yang, Qian

doi:10.1016/j.vaccine.2014.08.017

Cited by 39 publications

(37 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The traditional adjuvant, mineral oil, has been used in a commercial whole-cell killed Streptococcus agalactiae vaccine (AQUAVAC ® Strep Sa). In addition to Freund's complete and incomplete adjuvants (FCA and FIA;He et al 2014, Yi et al 2014, many other types of adjuvants have been used in tilapia S. agalactiae vaccination, such as aluminum-based adjuvants (Eldar et al 1995, He et al 2014) and nonmineral oil adjuvant Montanide ISA 763 (Table 1).…”

Section: Influence Of Adjuvantsmentioning

confidence: 99%

“…However, S. agalactiae recombinant vaccines usually require the use of adjuvants to provide appropriate protection (Table 1). For instance, He et al (2014) showed that recombinant truncated Sip (tSip) mixed with FIA and IP-injected provided very strong protection to tilapia (RPS = 90%) against Group B streptococcal infections, while tSip without adjuvant was only about half as effective (RPS = 50%). Similarly, Firdaus-Nawi et al (2013) showed that a feed-based vaccine with FIA provided a significantly higher protection (RPS = 100%) in tilapia than that without FIA (RPS = 57%).…”

Section: Influence Of Adjuvantsmentioning

confidence: 99%

See 1 more Smart Citation

Development of Streptococcus agalactiae vaccines for tilapia

Liu¹,

Zhu²,

Chen³

et al. 2016

Dis. Aquat. Org.

102

View full text Add to dashboard Cite

Vaccination is a widely accepted and effective method to prevent most pathogenic diseases in aquaculture. Various species of tilapia, especially Nile tilapia Oreochromis niloticus, are farmed worldwide because of their high consumer demand. Recently, the tilapia-breeding industry has been hampered by outbreaks of Streptococcus agalactiae infection, which cause high mortality and huge economic losses. Many researchers have attempted to develop effective S. agalactiae vaccines for tilapia. This review provides a summary of the different kinds of S. agalactiae vaccines for tilapia that have been developed recently. Among the various vaccine types, inactivated S. agalactiae vaccines showed superior protection efficiency when compared with live attenuated, recombinant and DNA vaccines. With respect to vaccination method, injecting the vaccine into tilapia provided the most effective immunoprotection. Freund's incomplete adjuvant appeared to be suitable for tilapia vaccines. Other factors, such as immunization duration and number, fish size and challenge dose, also influenced the vaccine efficacy.

show abstract

Section: Influence Of Adjuvantsmentioning

confidence: 99%

Section: Influence Of Adjuvantsmentioning

confidence: 99%

Development of Streptococcus agalactiae vaccines for tilapia

Liu¹,

Zhu²,

Chen³

et al. 2016

Dis. Aquat. Org.

102

View full text Add to dashboard Cite

show abstract

“…They require the help of adjuvants to enhance their immunogenicity [7,30]. Different adjuvants have been used in IWC-vaccine formulations for S. agalactiae in tilapia and these include Freund’s incomplete [22,28] and aluminum hydroxide gel (AH) [22] adjuvants. However, adjuvants have been shown to induce side effects in fish [31] and, hence, the search for other antigen delivery systems that do not require incorporation of adjuvants in vaccine formulation has attracted a lot of interest in fish vaccinology [7].…”

Section: Antigen Delivery Systemmentioning

confidence: 99%

“…It is highly conserved, having more than 90% sequence alignment homology between tilapia and mammalian strains of S. agalactiae [33]. He et al [22] produced a subunit vaccine using the Sip protein that produced high protection in tilapia while Yi et al [23] showed high protection in tilapia using the subunit vaccines encoding the fibrinogen binding protein A (FbsA) and α-enolase antigens. Similarly, Wang et al [24] produced a subunit vaccine against S. agalactiae using the phosphoglycerate kinase (PGK) protein expressed in the Escherichia coli plasmid and showed that combining PGK with IWC-vaccines significantly increased the survival of tilapia against S. agalactiae infection.…”

Section: Antigen Delivery Systemmentioning

confidence: 99%

An Overview of Vaccination Strategies and Antigen Delivery Systems for Streptococcus agalactiae Vaccines in Nile Tilapia (Oreochromis niloticus)

2016

View full text Add to dashboard Cite

Streptococcus agalactiae is an emerging infectious disease adversely affecting Nile tilapia (Niloticus oreochromis) production in aquaculture. Research carried out in the last decade has focused on developing protective vaccines using different strategies, although no review has been carried out to evaluate the efficacy of these strategies. The purpose of this review is to provide a synopsis of vaccination strategies and antigen delivery systems currently used for S. agalactiae vaccines in tilapia. Furthermore, as shown herein, current vaccine designs include the use of replicative antigen delivery systems, such as attenuated virulent strains, heterologous vectors and DNA vaccines, while non-replicative vaccines include the inactivated whole cell (IWC) and subunit vaccines encoding different S. agalactiae immunogenic proteins. Intraperitoneal vaccination is the most widely used immunization strategy, although immersion, spray and oral vaccines have also been tried with variable success. Vaccine efficacy is mostly evaluated by use of the intraperitoneal challenge model aimed at evaluating the relative percent survival (RPS) of vaccinated fish. The major limitation with this approach is that it lacks the ability to elucidate the mechanism of vaccine protection at portals of bacterial entry in mucosal organs and prevention of pathology in target organs. Despite this, indications are that the correlates of vaccine protection can be established based on antibody responses and antigen dose, although these parameters require optimization before they can become an integral part of routine vaccine production. Nevertheless, this review shows that different approaches can be used to produce protective vaccines against S. agalactiae in tilapia although there is a need to optimize the measures of vaccine efficacy.

show abstract

“…Nile tilapia (Oreochromis niloticus) is one of the most important economical fishes and widely cultured throughout the world [24]. In recent years, infectious disease caused by Streptococcus agalactiae has been severe, resulting in great economic loss and becoming a big obstacle to tilapia aquaculture [25].…”

mentioning

confidence: 99%